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Abstract. Standard therapy formalaria inUganda changed fromchloroquine to chloroquine+ sulfadoxine-pyrimethamine
in 2000, and artemether-lumefantrine in 2004, although implementation of each change was slow. Plasmodium falciparum
genetic polymorphisms are associated with alterations in drug sensitivity. We followed the prevalence of drug resistance-
mediating P. falciparum polymorphisms in 982 samples from Tororo, a region of high transmission intensity, collected from
three successive treatment trials conducted during 2003–2012, excluding samples with known recent prior treatment.
Considering transporter mutations, prevalence of the mutant pfcrt 76T, pfmdr1 86Y, and pfmdr1 1246Y alleles decreased
over time. Considering antifolate mutations, the prevalence of pfdhfr 51I, 59R, and 108N, and pfdhps 437G and 540E were
consistently high; pfdhfr 164L and pfdhps 581G were uncommon, but most prevalent during 2008–2010. Our data suggest
sequential selective pressures as different treatments were implemented, and they highlight the importance of genetic
surveillance as treatment policies change over time.
INTRODUCTION
Despite the recent endorsement of malaria elimination as a
worldwide goal, the malaria burden has not decreased notably
in Uganda, where Plasmodium falciparum is responsible for
most episodes of malaria, and millions of cases occur each
year.1 Uganda has undergone two recent changes in policy
for the treatment of uncomplicated malaria, driven by the
development of resistance to older antimalarials.2 In 2000,
chloroquine (CQ) was replaced by CQ plus sulfadoxine-
pyrimethamine (SP), and in 2004 this regimen was replaced by
the artemisinin-based combination therapy (ACT) artemether-
lumefantrine (AL), although implementation of new treat-
ment practices was slow. Alternate ACTs for uncomplicated
malaria in Uganda are artesunate-amodiaquine (AS-AQ) and
dihydroartemisinin-piperaquine (DP). Each ACT consists of
a potent and rapid-acting artemisinin and a longer-acting
partner drug.3 Leading ACTs have shown outstanding antima-
larial efficacy,4,5 but early signs of resistance to artemisinins,
manifested as delayed parasite clearance after therapy, have
been seen in parts of Southeast Asia,6 and resistance has been
seen to most ACT partner drugs.7
Resistance to a number of antimalarial drugs has been linked
to genetic polymorphisms in P. falciparum. Single nucleotide
polymorphisms (SNPs) in pfcrt and pfmdr1, which encode
putative transport proteins, affect responses to multiple drugs.
A single mutation, pfcrt 76T, is the key mediator of resistance
to CQ and AQ.8 In addition, polymorphisms in pfmdr1, which
is homologous to proteins that mediate drug sensitivity in
mammalian cells,9 modulate sensitivity of parasites to multiple
drugs.10,11 Considering pfmdr1 mutations that are common in
Africa, 86Y and 1246Y are associated with decreased sensitiv-
ity to CQ and AQ, but wild-type (WT) sequences at the same
alleles mediate decreased sensitivity to lumefantrine, meflo-
quine, and artemisinins.12–14 Another pfmdr1 polymorphism,
Y184F, is common, but of uncertain significance, and two
others, S1034C and N1042D, are seen in Asia, but rare
in Africa.9
In Uganda and many other African countries the preva-
lence of the key mediator of CQ resistance, pfcrt 76T,
increased to saturation levels by the 1990s.15–17 With cessation
of CQ use, reduction in the prevalence of pfcrt 76T has been
seen. Notably, in Malawi, over 8 years after CQ withdrawal,
the prevalence of parasites with pfcrt 76T decreased from
85% to 13%,18 and in 2005 excellent antimalarial efficacy of
CQ was shown.19 Decreases in the prevalence of pfcrt 76T
have also been seen in eastern Kenya and Zanzibar, although
changes have not been as dramatic as in Malawi.20,21 Changes
have also been seen in the prevalence of key pfmdr1 geno-
types in Kenya, Tanzania, and Zanzibar, with WT N86 and
D1246 genotypes increasing over time.11,21–23
The SNPs in folate enzyme genes are associated with
decreased sensitivity to antifolate antimalarials such as SP.24
Antifolate resistance develops in a stepwise manner. Parasites
containing five mutations, pfdhfr 51I, 59R, and 108N plus
pfdhps 437G and 540E, which together mediate clinically rel-
evant resistance, have recently been seen to be common in
East Africa and near fixation in Uganda,16,25 where continued
selection is presumably caused by continued use of antifolates
for intermittent preventive therapy and other uses. However,
mutations that mediate a higher level of resistance and are
seen elsewhere, notably pfdhfr I164L and pfdhps A581G, are
generally uncommon in Africa,26 although some reports have
noted increased prevalence in parts of east Africa.27,28 Nota-
bly, pfdhfr 164L was reported in 14% of P. falciparum isolates
collected from symptomatic patients in southwestern Uganda
in 2005.29
Considering the impacts of parasite polymorphisms in both
transporter and folate genes on drug sensitivity and changing
malaria treatment practices over time, it was of interest to
examine the prevalence of key SNPs in Uganda over time.
We therefore examined sequences of interest in P. falciparum
isolates from patients enrolled in drug efficacy trials from
2003 to 2012 in a high malaria transmission area of Uganda.
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MATERIALS ANDMETHODS
Clinical trials. We analyzed 982 archived P. falciparum iso-
lates obtained from treatment trials in Tororo District. Details
of the clinical studies have been published (Table 1).30–33 For
the first study, which enrolled patients ³ 6 months of age with
uncomplicated P. falciparum malaria from December 2002 to
May 2004 and compared the efficacies of CQ+SP, AQ+SP,
and AS+AQ,31 we analyzed 198 pretreatment DNA samples
collected from September to November 2003 for pfmdr1 and
pfdhps 581 polymorphisms, and included data on other poly-
morphisms that were already published.16 For the second
study, which enrolled patients 1–10 years of age that pre-
sented with uncomplicated P. falciparum malaria from
December 2004 to July 2005 and compared the efficacies of
AS+AQ, and AL,32 we analyzed 201 pretreatment DNA
samples for pfdhfr and pfdhps polymorphisms, and included
data on pfcrt and pfmdr1 SNPs that were already pub-
lished.34 For the third study, a longitudinal trial in which 351
children 4–12 months of age were enrolled and randomized
to receive either AL or DP for each episode of uncompli-
cated malaria,33 we analyzed 584 samples, including 204 from
all first episodes of falciparum malaria and 380 from all
recurrent episodes presenting 84 or more days after a prior
treatment. For this trial, in a subset of samples that were
genotyped, < 1% of recurrent infections within 28 days were
caused by recrudescence; we anticipate that no infections
occurring ³ 84 days after a prior infection were the result
of recrudescence.33,35
Target gene amplification and mutation analysis. Parasite
DNA was extracted from dried filter paper blood spots using
Chelex, as previously described.36 The DNA from control
strains 3D7, Dd2, 7G8, FCR3, V1/S, K1, and Peru was
obtained from the Malaria Research and Reference Reagent
Resource Center. Genes of interest were amplified, and poly-
morphisms in pfcrt, pfmdr1, pfdhfr, and pfdhps were analyzed
by nested polymerase chain reaction (PCR) followed by
restriction fragment length polymorphism (RFLP) analysis,
as previously described.37–39 Target sequences were amplified
(see Supplemental Table 1 for primers), and PCR products
were treated with polymorphism-specific restriction endonu-
cleases (ApoI for pfcrt K76T; AflIII, DraI, and BglII for
pfmdr1 N86Y, Y184F, and D1246Y, respectively; MluCI,
XmnI, BsrI and DraI for pfdhfr N51I, C59R, S108N and
I164L, respectively; and AvaII, FokI and BstUI for pfdhps
A437G, K540E and A581G, respectively). Reaction products
were resolved on 2.5% agarose gels, and electrophoretic band
patterns were categorized as WT, mixed, or mutant genotypes
by visual inspection of gels and comparison with DNA from
control strains.
Data analysis. Data were entered into a Microsoft
(Microsoft Corp., Redmond, WA) access database and
exported into Statistical Package for the Social Sciences
(SPSS Inc., Chicago, IL) software 17.0, which was used for
analysis. For these analyses, mixed genotypes were grouped
with either mutant orWT, as indicated. Graphs were generated
with GraphPad Prism 5.0 (GraphPad Prism, La Jolla, CA).
Temporal changes in SNP frequencies were analyzed using
logistic regression with date of collection as a continuous or
categorical variable, as indicated, to evaluate for trends over
time or differences between discrete time periods, respectively.
A P value < 0.05 was considered statistically significant.
RESULTS
We evaluated the prevalence of polymorphisms of interest
in pfcrt, pfmdr1, pfdhfr, and pfdhps from P. falciparum iso-
lates collected in three clinical trials, all conducted in Tororo
District over the course of a decade during which standard
antimalarial treatment in Uganda underwent major changes.
To minimize the influence of prior therapies on parasite
genetics, samples were collected before treatment in the two
older trials, and in the newer longitudinal trial, samples were
from first episodes of malaria and from episodes ³ 84 days
since a prior episode. The SNPs of interest were categorized
as WT, mixed, or mutant, based on sequences of the reference
3D7 strain (Table 2).
For pfcrt K76T, the prevalence of mutant parasites was
nearly 100% throughout the early years of observation, con-
sistent with other reports from Uganda,15,16,40,41 and likely
due in part to widespread use of chloroquine even after the
national treatment policy changed in 2004. The prevalence of
WT and mixed K76T genotypes increased modestly from 2008
to 2011, and then a marked change was seen in 2012, with
16% mixed and 17% pure WT genotypes seen (Figure 1).
Considering the period from 2007 to 2012, the probability of
being infected with a WT or mixed (versus mutant) genotype
increased significantly over time (P < 0.001).
For pfmdr1, the N86Y, Y184F, and D1246Y alleles were
highly polymorphic throughout the period of observation.
Although results varied from year to year, clear patterns were
seen at the N86Y and D1246Y alleles, with increasing preva-
lence of WT genotypes over time (Figure 1). At Y184F,
increasing prevalence of the mutant genotype was seen. Con-
sidering the entire period of observation, statistically signifi-
cant increases in the probability of infection with a WT or
mixed genotype for the N86Y (P < 0.001) and D1246Y (P <
0.001) alleles, and with a mutant (versus mixed or WT) geno-
type for the Y184F allele (P < 0.001) were seen. Prevalence of
Table 1
Description of trials that provided samples for the molecular study*
Antimalarial regimens studied
Baseline study characteristics CQ+SP vs. AQ+SP vs. AS+AQ† AL vs. AS+AQ† AL vs. DP‡
Study period 2002–04 2004–05 2007–12
Age at enrollment ³ 6 months 1–10 years 4–12 months
Number of participants 347 403 351
Median age (years) 1.27 1.83 0.98
Geometric mean parasite density 18,484/mL 22,071/mL 16,349/mL
Samples successfully genotyped 189/198 (95%) 188/201 (93%) 561/584 (96%)
*CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaquine; AL = artemether-lumefantrine; DP = dihydroartemisinin-piperaquine.
†Pretreatment samples obtained from clinical studies.31,32
‡Samples from all first episodes and recurrent episodes ³ 84 days after prior treatment.33
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the 86Y/Y184/1246Y haplotype decreased markedly over
time, with increases in haplotypes including WT sequences at
positions 86 and 1246 (Table 3). Based on known selective
effects of antimalarial drugs that have been commonly used
in Uganda, these results suggest decreasing selective pressure
of CQ and/or increasing selective pressure of AL over
time in Uganda.
For mutations associated with resistance to antifolate anti-
malarials, five well-described mutations in pfdhfr (N51I,
C59R, S108N) and pfdhps (A437G, K540E) were all very
common throughout the period of observation (Table 2).
Considering uncommon genotypes associated with high-level
resistance, both pfdhfr 164L and pfdhps 581G were nearly
absent early and late in our study, but more common from
2008 to 2010, with peak prevalence of mixed or mutant
sequences at pfdhfr 164 at 9–12% in 2009 and 2010, and at
pfdhps position 581 at 11–13% in 2008–2011 (Figure 2). The
prevalence of the pfdhfr 164 WT genotype was significantly
lower in 2009–10 than in other years (P < 0.001) and the
prevalence of the pfdhps 581 WT genotype was significantly
lower in 2009–12 than in earlier years (P = 0.01).
DISCUSSION
We examined changes in the prevalence of P. falciparum
polymorphisms associated with drug resistance over a decade
during which standard antimalarial treatment in Uganda
underwent major changes. All evaluated samples were from
the same region of Uganda, and from patients without known
recent antimalarial treatment before analysis, limiting selec-
tive pressure from prior therapy, and thus providing a reason-
able assessment of the prevalence of polymorphisms in
parasites circulating in Tororo each year. Important changes
were seen in the prevalence of a number of SNPs of interest.
Table 2
Proportions of patients infected with Plasmodium falciparum parasites containing polymorphisms in pfcrt, pfmdr1, pfdhfr, and pfdhps*
Genotype
Year
2003–2004† 2005‡ 2007 2008 2009 2010 2011 2012
pfcrt K76T
WT 0 0 0 0 4 (4%) 0 0 13 (17%)
Mixed 1 (1%) 0 0 3 (2%) 2 (2%) 4 (4%) 9 (8%) 12 (16%)
Mutant 79 (99%) 201 (100%) 38 (100%) 144 (98%) 87 (94%) 104 (96%) 102 (92%) 52 (67%)
Pfmdr1 N86Y
WT 20 (10%) 19 (9%) 12 (32%) 34 (23%) 23 (26%) 48 (44%) 52 (47%) 40 (51%)
Mixed 136 (71%) 76 (38%) 7 (19%) 88 (61%) 27 (30%) 41 (37%) 41 (37%) 32 (41%)
Mutant 36 (19%) 106 (53%) 18 (49%) 23 (16%) 39 (44%) 21 (19%) 18 (16%) 6 (8%)
Pfmdr1 Y184F
WT 141 (75%) 169 (85%) 25 (68%) 103 (71%) 75 (83%) 41 (37%) 63 (59%) 50 (68%)
Mixed 43 (23%) 28 (14%) 7 (19%) 22 (15%) 6 (7%) 45 (41%) 7 (7%) 4 (6%)
Mutant 3 (2%) 3 (1%) 5 (13%) 20 (14%) 9 (10%) 25 (22%) 36 (34%) 19 (26%)
Pfmdr1 D1246Y
WT 3 (2%) 32 (17%) 9 (23%) 35 (24%) 16 (17%) 22 (19%) 22 (20%) 42 (53%)
Mixed 89 (48%) 80 (40%) 12 (31%) 50 (34%) 22 (23%) 55 (50%) 53 (48%) 27 (34%)
Mutant 93 (50%) 86 (43%) 18 (46%) 61 (42%) 58 (60%) 34 (31%) 35 (32%) 10 (13%)
Pfdhfr N51I
WT 0 1 (1%) 0 1 (1%) 1 (1%) 0 0 0
Mixed 5 (6%) 5 (2%) 0 0 0 1 (1%) 0 0
Mutant 75 (94%) 185 (97%) 34 (100%) 144 (99%) 92 (99%) 110 (99%) 109 (100%) 79 (100%)
Pfdhfr C59R
WT 24 (7%) 13 (7%) 3 (8%) 4 (3%) 6 (7%) 10 (9%) 5 (4%) 6 (8%)
Mixed 122 (37%) 60 (31%) 1 (3%) 9 (6%) 3 (3%) 12 (11%) 14 (13%) 5 (6%)
Mutant 187 (56%) 117 (62%) 33 (89%) 132 (91%) 84 (90%) 87 (80%) 92 (83%) 65 (86%)
Pfdhfr S108N
WT 0 1 (1%) 0 0 0 1 (1%) 0 0
Mixed 0 4 (2%) 20 (59%) 29 (23%) 10 (11%) 18 (16%) 10 (9%) 2 (2%)
Mutant 80 (100%) 186 (97%) 14 (41%) 99 (77%) 83 (89%) 92 (83%) 101 (91%) 77 (98%)
Pfdhfr I164L
WT 80 (100%) 152 (99%) 34 (100%) 137 (99%) 83 (91%) 98 (88%) 105 (100%) 77 (100%)
Mixed 0 2 (1%) 0 1 (1%) 7 (8%) 12 (11%) 0 0
Mutant 0 0 0 0 1 (1%) 1 (1%) 0 0
Pfdhps A437G
WT 5 (2%) 3 (2%) 0 1 (1%) 1 (1%) 1 (1%) 1 (1%) 0
Mixed 48 (14%) 24 (12%) 0 1 (1%) 1 (1%) 2 (2%) 1 (1%) 4 (5%)
Mutant 280 (84%) 170 (86%) 33 (100%) 142 (98%) 91 (98%) 108 (97%) 108 (98%) 75 (95%)
Pfdhps K540E
WT 8 (2%) 2 (1%) 0 0 0 1 (1%) 1 (1%) 0
Mixed 86 (26%) 25 (13%) 0 6 (4%) 4 (4%) 4 (4%) 14 (13%) 3 (4%)
Mutant 239 (72%) 165 (86%) 33 (100%) 138 (96%) 89 (96%) 106 (95%) 95 (86%) 76 (96%)
Pfdhps A581G
WT 193 (100%) 195 (98%) 37 (100%) 129 (88%) 83 (89%) 97 (87%) 95 (88%) 76 (98%)
Mixed 0 1 (1%) 0 17 (11%) 9 (10%) 4 (4%) 9 (8%) 1 (2%)
Mutant 0 2 (1%) 0 1 (1%) 1 (1%) 10 (9%) 4 (4%) 0
WT = wild-type.
*Data shown are numbers (proportions in parentheses) of samples with each genotype.
†Data from 2003–2004 (samples obtained from November 2003 to May, 2004) are combined.
‡Data obtained from December 2004 to July 2005 are included for 2005; 98% of samples from this trial were collected in 2005.
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For pfcrt K76T, which is known to mediate CQ and AQ
resistance, WT parasites were nearly absent in the early years
of observation, but these became much more common by
2012. For pfmdr1 N86Y and D1246Y, which impact upon
sensitivity to multiple drugs, the prevalence of WT alleles
increased steadily over time. For polymorphisms in pfdhfr
and pfdhps, which mediate resistance to antifolates, five well-
described mutations remained common over time, and muta-
tions at two additional alleles associated with high level
resistance showed modest prevalence only from 2008–11. Over-
all, the identified changes in prevalence seem to be consistent
with differing selective drug pressures caused by changes in
treatment practices in Uganda over time.
How can we explain the observed changes in the prevalence
of P. falciparum drug resistance-mediating SNPs in Uganda
over time? The mutant pfcrt 76T genotype persisted in
Uganda at high (> 90%) prevalence levels through 2011, long
after it had decreased elsewhere in East Africa. For example,
the prevalence of the 76T genotype was 63% in eastern Kenya
in 2008,22 63% in Zanzibar in 2010,21 and 32% in western
Kenya in 2011.11 The persistence of the mutant pfcrt 76T
genotype in Uganda suggests that continued selective pres-
sure from CQ persisted long after the national treatment pol-
icy changed in 2004, when the standard therapy for malaria
was changed from CQ + SP to AL. The CQ remains available
in Uganda, and in fact it continues to be recommended for
regular chemoprophylaxis in children with sickle cell dis-
ease.42 Very recently, the prevalence of parasites with the
CQ-sensitive pfcrt K76 genotype increased markedly in
Tororo, suggesting a decrease in community use of CQ.
For pfmdr1, the prevalence of mutant 86Y and 1246Y geno-
types gradually decreased in Uganda from 2003 to 2012.
These changes were likely due both to decreased use of CQ
and gradual establishment of AL as the standard antimalarial
drug in Tororo, because both decreasing CQ exposure and
increased lumefantrine exposure will select for WT sequences
at these alleles.3,43,44 In other parts of East Africa, the preva-
lence of pfmdr1 N86 and D1246 have been observed to
increase following widespread use of ACTs.11,23,45 Of note,
pfmdr1 WT genotypes have been associated with decreased
sensitivity to lumefantrine.46,47 Taken together, available data
suggest that, although the efficacies of leading ACTs appear
to remain excellent, parasites in East Africa are undergoing
changes rendering them less sensitive to lumefantrine. Con-
tinued selection may lead to highly resistant parasites, jeopar-
dizing the antimalarial efficacy of AL, the first-line therapy
for malaria in Uganda and surrounding countries.
Considering changes in the prevalence of SNPs that medi-
ate antifolate resistance, five well-characterized mutations in
pfdhfr (N51I, C59R, and S108N) and pfdhps (A437G, K540E)
were very common in Tororo throughout the last 10 years.
These data suggest continued strong selective pressure despite
the withdrawal of SP from treatment guidelines in 2004. Of
interest was whether selection of additional polymorphisms in
Figure 1. Prevalence of polymorphisms over time at codon 76 of pfcrt, and codons 86, 184, and 1246 of pfmdr1.
Table 3
Pfmdr1 haplotype distribution over time
Year 86Y/1246Y N86/D1246 N86/184F/D1246 86Y/Y184/1246Y
2003 15/180 (8%) 0/180 (0%) 0/197 (0%) 70/197 (36%)
2005 70/198 (35%) 15/198 (8%) 2/197 (1%) 67/197 (34%)
2007 13/37 (35%) 7/37 (19%) 1/37 (3%) 12/37 (32%)
2008 13/144 (9%) 19/144 (13%) 8/150 (5%) 11/150 (7%)
2009 24/89 (30%) 9/89 (10%) 3/87 (4%) 23/87 (26%)
2010 9/110 (8%) 14/110 (13%) 0/110 (0%) 3/110 (3%)
2011 9/110 (8%) 10/110 (9%) 4/105 (4%) 5/105 (5%)
2012 2/78 (3%) 22/78 (28%) 7/73 (10%) 0/73 (0%)
Data from 2003–2004 and late 2004–2005 were combined as explained in Table 2. The
results shown represent the proportion and percentage of each haplotype found among all
those with successful analysis for each allele, considering only results with pure wild-type
(WT) or mutant genotypes.
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pfdhfr or pfdhps was seen, in particular the pfdhfr 164L and
pfdhps 581G mutations that are associated with high-level
antifolate resistance.24 In Kenya, an increase in prevalence of
the five common mutations, and also emergence of dhps 581G,
was reported over a 13-year period of observation,48 despite
withdrawal of SP for the treatment of malaria in 2006. Other
reports have noted a fairly high prevalence of SNPs that medi-
ate high-level antifolate resistance in some settings, including a
pfdhfr 164L prevalence of 14% in P. falciparum from an area
of Uganda with low malaria transmission intensity29 and mod-
est prevalence of both the pfdhfr 164L and pfdhps 581G muta-
tions in human immunodeficiency virus (HIV)-infected
Ugandan children receiving regular trimethoprim-sulfameth-
oxazole prophylaxis.49,50 In other recent studies from East
Africa, the prevalence of pfdhps 581G was > 50% in samples
from eastern Kenya and Tanzania.27,28 In our results from
Tororo, the pfdhfr 164L and pfdhps 581G mutations were very
uncommon, except for increased prevalence from 2008 to 2011.
Reasons for continued antifolate selective pressure likely
include continued use of SP to treat malaria, treatment of
bacterial infections with antifolates, use of SP in intermittent
preventive treatment in pregnant women, which remains the
World Health Organization (WHO) policy, and widespread
use of another antifolate, trimethoprim-sulfamethoxazole, as
prophylaxis against opportunistic infections in HIV-infected
individuals. The decreased prevalence of both the pfdhfr 164L
and pfdhps 581G mutations in Tororo in the most recent years
suggests decreasing use of SP to treat malaria quite recently
and fitness disadvantages of genotypes that mediate the highest
levels of antifolate resistance; these fitness disadvantages may
most effectively prevent selection in areas with very high
malaria transmission intensity, such as Tororo.7
Our study had some limitations. First, samples were col-
lected from studies with different designs. In the two older
treatment efficacy trials subjects were enrolled and samples
obtained immediately before treatment of malaria, but infor-
mation on prior treatment before enrollment was necessarily
limited. The more recent trial was a longitudinal trial in which
children were treated with the same regimen, either AL or
DP, for every episode of malaria over 5 years. In this trial, to
limit impacts of prior treatments on infecting parasites, we
studied only parasites causing first infections in the study and
those without prior therapy within 84 days. Another limita-
tion was that data were derived from a combination of older
and recent assays, and for the oldest trial different numbers of
samples were assessed for different alleles. Although we used
Figure 2. Prevalence of polymorphisms over time in the indicated alleles of pfdhfr and pfdhfr.
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the same RFLP methods for all assessments, assays done at
different points in time after sample collection may have led
to somewhat different results, in particular in the case of
minority strains within populations.
Despite some limitations, our data offer the best available
description of changes in the prevalence of key resistance-
mediating P. falciparum polymorphisms over time in Uganda.
Indeed, parasites changed notably from 2003 to 2012. Our
results suggest continued use of CQ and SP well beyond the
establishment of AL as the national treatment regimen in
2004. However, our most recent results suggest decreasing
selective pressure from both CQ and SP, with increasing prev-
alence of the pfcrt K76 WT genotype and loss of folate gene
polymorphisms associated with high level resistance. In addi-
tion, increasing prevalence of the WT pfmdr1 N86 and D1246
alleles has been seen over time. These results are reassuring,
in suggesting that recommended use of AL to treat uncompli-
cated malaria has increased. However, the results also raise
the concern that continued heavy use of AL may select for
parasites with decreased lumefantrine sensitivity, potentially
leading to AL treatment failures. Continued surveillance of
P. falciparum polymorphisms will be important, both to pro-
vide insight into the evolution of drug resistance and to offer
feedback regarding national treatment practices. In future
surveillance higher throughput assays,51 and deep sequencing
methods to identify minority strains,52 may improve our abil-
ity to assess changes in allele prevalence over time.
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